Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Gilead Sciences
Gilead Sciences
Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline
BioSpace
Fri, 04/26/24 - 11:17 am
Gilead Sciences
earnings
FDA mandates label updates on CAR-T cancer therapies
Reuters
Thu, 04/18/24 - 10:34 pm
CAR-T
FDA
warning
cancer
Gilead Sciences
Bristol Myers Squibb
2seventybio
Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24
Fierce Biotech
Wed, 04/3/24 - 11:36 am
biotech
M&A
IPOs
CG Oncology
Kyverna Therapeutics
Contineum Therapeutics
Boundless Bio
CymaBay Therapeutics
Gilead Sciences
MorphoSys
Novartis
Fusion Pharmaceuticals
AstraZeneca
Ambryx
JNJ
Inhibrix
Aventis
Gilead dives deeper into Nurix protein degrader collab, paying $15M for 2-year extension
Fierce Biotech
Tue, 04/2/24 - 11:38 am
Gilead Sciences
Nurix Therapeutics
protein degradation
FDA approves Gilead's Vemlidy drug for children with hepatitis B
Investing.com
Thu, 03/28/24 - 05:08 pm
Gilead Sciences
FDA
Vemlidy
hepatitis B
pediatric
Gilead bets on Xilio cancer drug as biotech restructures
BioPharma Dive
Thu, 03/28/24 - 11:54 am
Gilead Sciences
Xilio Therapeutics
cancer
immunotherapy
restructuring
XTX301
solid tumors
Gilead CAR-T cancer therapy capacity to quadruple by 2026
Reuters
Fri, 03/15/24 - 10:57 am
Gilead Sciences
cell therapy
cancer
drug manufacturing
Study: Gilead antiviral drug shows promise as a treatment for Ebola Sudan
Stat
Thu, 03/14/24 - 06:25 pm
Gilead Sciences
obeldesivir
Ebola Sudan
antivirals
Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab
Fierce Biotech
Wed, 03/6/24 - 11:30 am
Gilead Sciences
Merus
T-cell engager
Gilead Secures $210M from VC to Build Trodelvy’s Clinical Case in NSCLC
BioSpace
Fri, 03/1/24 - 11:48 am
Gilead Sciences
funding
Trodelvy
non-small cell lung cancer
6 first-half 2024 oncology data readouts to watch
BioSpace
Mon, 02/26/24 - 11:20 am
oncology
clinical trials
Daiichi Sankyo
AstraZeneca
Enhertu
metastatic breast cancer
Gilead Sciences
Trodelvy
bladder cancer
GSK
Zejula
Jemperli
ovarian cancer
Roche
tiragolumab
Tecentriq
non-small cell lung cancer
Cue Biopharma
CUE-101
head and neck cancer
Elicio Therapeutics
ELI-002
solid tumors
PhRMA, navigating turbulence, taps Gilead CEO to helm board of directors
Fierce Pharma
Wed, 02/21/24 - 10:43 pm
PhRMA
lobbying
Daniel O'Day
Gilead Sciences
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials
Reuters
Thu, 02/15/24 - 07:14 pm
Gilead Sciences
magrolimab
solid tumors
Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med
Fierce Biotech
Mon, 02/12/24 - 11:53 am
Gilead Sciences
CymaBay Therapeutics
M&A
liver disease
seladelpar
primary biliary cholangitis
FDA puts hold on Gilead's blood cancer therapy trials
Reuters
Wed, 02/7/24 - 09:20 pm
Gilead Sciences
FDA
clinical trials
magrolimab
blood cancer
Gilead will not buy Tizona after paying $300M for the right to do so
Fierce Biotech
Wed, 02/7/24 - 11:17 am
Gilead Sciences
Tizona Therapeutics
M&A
oncology
Amgen earnings boosted by Horizon deal, Gilead quarterly revenue drops
Medical Marketing and Media
Tue, 02/6/24 - 11:41 pm
Amgen
Gilead Sciences
earnings
Horizon Therapeutics
M&A
Gilead-backed Kyverna Therapeutics aims for $857.3 mln valuation in upsized IPO
Reuters
Tue, 02/6/24 - 09:17 am
Kyvera Therapeutics
IPOs
Gilead Sciences
autoimmune diseases
Gilead invests $320M in Arcus to increase stake to 33%
Medical Marketing and Media
Wed, 01/31/24 - 10:32 pm
Gilead Sciences
Arcus Biosciences
immuno-oncology
Gilead’s Kite Gets FDA Approval for Faster CAR T Therapy Manufacturing
BioSpace
Wed, 01/31/24 - 11:58 am
Gilead Sciences
Kite Pharma
FDA
drug manufacturing
Yescarta
CAR-T
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »